These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27129362)

  • 1. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.
    Johannsson G; Lennernäs H; Marelli C; Rockich K; Skrtic S
    Eur J Endocrinol; 2016 Jul; 175(1):85-93. PubMed ID: 27129362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial.
    Werumeus Buning J; Touw DJ; Brummelman P; Dullaart RPF; van den Berg G; van der Klauw MM; Kamp J; Wolffenbuttel BHR; van Beek AP
    Metabolism; 2017 Jun; 71():7-16. PubMed ID: 28521880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.
    Mah PM; Jenkins RC; Rostami-Hodjegan A; Newell-Price J; Doane A; Ibbotson V; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):367-75. PubMed ID: 15355454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
    Johannsson G; Bergthorsdottir R; Nilsson AG; Lennernas H; Hedner T; Skrtic S
    Eur J Endocrinol; 2009 Jul; 161(1):119-30. PubMed ID: 19383806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers.
    Jung C; Greco S; Nguyen HH; Ho JT; Lewis JG; Torpy DJ; Inder WJ
    BMC Endocr Disord; 2014 Nov; 14():91. PubMed ID: 25425285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults.
    Melin J; Parra-Guillen ZP; Hartung N; Huisinga W; Ross RJ; Whitaker MJ; Kloft C
    Clin Pharmacokinet; 2018 Apr; 57(4):515-527. PubMed ID: 28762136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
    Espiard S; McQueen J; Sherlock M; Ragnarsson O; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Skrtic S; Wahlberg J; Stewart PM; Johannsson G
    J Clin Endocrinol Metab; 2021 Mar; 106(3):814-825. PubMed ID: 33236103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors.
    Lennernäs H; Skrtic S; Johannsson G
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):749-58. PubMed ID: 18611115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency.
    Thomson AH; Devers MC; Wallace AM; Grant D; Campbell K; Freel M; Connell JM
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):789-96. PubMed ID: 17437510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.
    Michelet R; Melin J; Parra-Guillen ZP; Neumann U; Whitaker JM; Stachanow V; Huisinga W; Porter J; Blankenstein O; Ross RJ; Kloft C
    Eur J Endocrinol; 2020 Oct; 183(4):357-368. PubMed ID: 32621587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial.
    Werumeus Buning J; Konopka KH; Brummelman P; Koerts J; Dullaart RPF; van den Berg G; van der Klauw MM; Tucha O; Wolffenbuttel BHR; van Beek AP
    PLoS One; 2017; 12(7):e0180326. PubMed ID: 28686664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.
    Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Ragnarsson O; Skrtic S; Wahlberg J; Achenbach H; Uddin S; Marelli C; Johannsson G
    Eur J Endocrinol; 2017 Jun; 176(6):715-725. PubMed ID: 28292927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circadian variation in serum cortisol during hydrocortisone replacement is not attributable to changes in cortisol-binding globulin concentrations.
    Chung TT; Gunganah K; Monson JP; Drake WM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):496-500. PubMed ID: 26603673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.
    Simon N; Castinetti F; Ouliac F; Lesavre N; Brue T; Oliver C
    Clin Pharmacokinet; 2010 Jul; 49(7):455-63. PubMed ID: 20528006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified-release hydrocortisone to provide circadian cortisol profiles.
    Debono M; Ghobadi C; Rostami-Hodjegan A; Huatan H; Campbell MJ; Newell-Price J; Darzy K; Merke DP; Arlt W; Ross RJ
    J Clin Endocrinol Metab; 2009 May; 94(5):1548-54. PubMed ID: 19223520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.